Please use this identifier to cite or link to this item:
Title: Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments
Authors: Matusevich, O V
Egorov, V V
Gluzdikov, I A
Titov, M I
Shtro, A A
Slita, A V
Dukov, M I
Shurygina, A-P S
Smirnova, T D
Kudryavtsev, I V
Vasin, A V
Kiselev, O I
Zarubaev, Vladimir V. 
Keywords: Antiviral peptides;Influenza A;Influenza A polymerase;PB1
Issue Date: Jan-2015
Publisher: Elsevier Masson
Journal: Antiviral Research 
Abstract: This study is devoted to the antiviral activity of peptide fragments from the PB1 protein - a component of the influenza A RNA polymerase. The antiviral activity of the peptides synthesized was studied in MDCK cell cultures against the pandemic influenza strain A/California/07/2009 (H1N1) pdm09. We found that peptide fragments 6-13, 6-14, 26-30, 395-400, and 531-540 of the PB1 protein were capable of suppressing viral replication in cell culture. Terminal modifications i.e. N-acetylation and C-amidation increased the antiviral properties of the peptides significantly. Peptide PB1 (6-14) with both termini modified showed maximum antiviral activity, its inhibitory activity manifesting itself during the early stages of viral replication. It was also shown that the fluorescent-labeled analog of this peptide was able to penetrate into the cell. The broad range of virus-inhibiting activity of PB1 (6-14) peptide was confirmed using a panel of influenza A viruses of H1, H3 and H5 subtypes including those resistant to oseltamivir, the leading drug in anti-influenza therapy. Thus, short peptide fragments of the PB1 protein could serve as leads for future development of influenza prevention and/or treatment agents.
ISSN: 0166-3542
DOI: 10.1016/j.antiviral.2014.10.015
Appears in Collections:Journal articles

Show full item record


checked on May 14, 2019

Page view(s)

checked on May 20, 2019

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.